ISLAMABAD, July 27 (online): According to a new study, a Chinese phase II clinical trial of a COVID-19 vaccine candidate has shown that it is safe and induces an immune response. With over 15 million confirmed cases of the new coronavirus, SARS-CoV-2, and more than 624,000 COVID-19 deaths globally, scientists around the world are competing against time to fast-track the development of new treatments to combat the disease. Globally, scientists are developing about 250 candidate vaccines against SARS-CoV-2 infection. Of these, to date, at least 17 are under evaluation in clinical trials. The authors of the recent study aimed to evaluate the safety and efficacy of a vaccine candidate called adenovirus type-5-vectored COVID-19 vaccine (Ad5-vectored COVID-19 vaccine). They also wanted to determine the most appropriate dose for a phase III trial in the coming months. Biologics developed the Ad5-vectored COVID-19 vaccine. It uses a weakened human common cold virus (adenovirus) that produces an immune system response, including antibodies, to fight off the coronavirus “The Beijing approach is based on the backbone of a conventional human, common cold virus to which some people have preexisting antibodies, and they, therefore, make a lower response in some people to the vaccine because people … Continue reading COVID-19 vaccine is safe and triggers immune response in human trial: Research